No Data
No Data
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
MeiHua Holdings GroupLtd's (SHSE:600873) Sluggish Earnings Might Be Just The Beginning Of Its Problems
MeiHua Holdings Group Co.,Ltd's (SHSE:600873) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings. SHSE
Meihua Biotech (600873): The leading multi-category layout in the global amino acid industry continues to gain strength
Key investment points: Mainly engaged in amino acid products, leading production capacity in the world. The company's products are mainly amino acids, taking into account the development of multiple categories, forming a business centered on animal nutritional amino acids, flavoring products, human medical amino acids, colloidal polysaccharides, etc.
Meihua Biotech (600873.SH): Relevant shareholders increased their total share holdings by 489.191,000 yuan
Gelonghui, April 10 | Meihua Biotech (600873.SH) announced that as of the disclosure date of this announcement, half of the implementation period of this increase plan has passed. Some holdings increase their holdings by a total of 489.191,000 yuan (including transaction fees) through the Shanghai Stock Exchange trading system through centralized bidding. The increase amount has reached and exceeded half of the lower limit of the increase in holdings plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement this holdings increase plan.
104 shares received a buying rating from brokerage firms, and Meihua Biotech's target increase of 54.74%
According to Wind data, on April 9, a total of 104 stocks received a brokerage purchase rating, of which 31 stocks announced target prices. Based on the highest target price, Meihua Biotech, Hengli Petrochemical, and Jiuzhou Pharmaceutical ranked first in terms of target increases of 54.74%, 49.27%, and 46.21%, respectively. Judging from the direction of rating adjustments, the ratings of 95 stocks remained unchanged, the rating of 1 individual stock was raised, and 8 stocks were rated for the first time. In addition, 19 individual stocks received attention from many brokerage firms. **** Mouse Electric, China Exemption, and Juneyao Airlines received the highest number of ratings, with 7, 4, and 4 brokerage firms respectively commenting
Meihua Biotech (600873): Performance is in line with market expectations, and the price difference between alcohol and lysine continues to rise
Incident: On the evening of April 8, the company released its 2024 quarterly report. In the first quarter, the company achieved operating income of 6.5 billion yuan, a year-on-year decrease of 6.7%; realized net profit of 750 million yuan, a year-on-year decrease of 6.1%; achieved no deduction
No Data